Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888929 | 0.83 | NLRP3 (0.47) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL20400046 | 0.77 | NLRP3 (0.39) | NLRP3ALOX5ALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL18209909 | 0.76 | NLRP3 (0.38) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL20939381 | 0.75 | NLRP3 (0.42) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL22021007 | 0.74 | NLRP3 (0.40) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL20400002 | 0.72 | CDC7 (0.33) | CA12CA1CA2CA9ALOX5 | |
| SCHEMBL24978765 | 0.71 | NLRP3 (0.37) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL20828220 | 0.71 | ALOX5 (0.41) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL18215107 | 0.70 | ALOX5 (0.40) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL28396680 | 0.69 | NLRP3 (0.39) | NLRP3ALOX5ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571187-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220306649-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3851434-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | Genentech, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11040985-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040985-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190337965-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2019-11-07 | — | — | US | disclosed |
| WO-2018136890-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | JECURE THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337965-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | NLRP3 8/4885CA12 4567/4885CA1 3177/4885 |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | NLRP3 8/4885CA12 4567/4885CA1 3177/4885 |
| US-11040985-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | NLRP3 8/4885CA12 4567/4885CA1 3177/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | NLRP3 8/4885CA12 4567/4885CA1 3177/4885 |
| US-20220306649-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | NLRP3 8/4885CA12 4567/4885CA1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.